eClinical Solutions Market by Product (CDMS, EDC, CTMS, eCOA, RTSM, eTMF, Safety), Deployment (On premise, Cloud), Application (Collection, Operations, Analytics), Trial Phase, End user (Pharma, Biotech, Med Devices), & Region - Global Forecast to 2029
세계 eClinical 솔루션 시장 규모는 예측 기간 동안 13.7%의 높은 CAGR로 성장하여 2024년 116억 달러에서 2029년 221억 달러에 이를 것으로 예상됩니다.
성장 원동력으로는 모든 임상 연구의 운영 비용과 규제 의무 증가, 임상 연구를 위한 혁신적인 소프트웨어 솔루션의 채택, 임상시험에 대한 정부 지원, 임상 데이터 표준화 및 품질 향상에 대한 필요성 증가, 제약 바이오테크놀러지 기업의 연구 개발 비용 증가, eClinical 솔루션을 구현하고 관리할 수 있는 숙련된 연구자 부족, eClinical 솔루션의 이점에 대한 인식 부족 등이 있습니다. eClinical 솔루션의 높은 구현률, 이러한 솔루션을 구현하고 관리할 수 있는 숙련된 전문가 부족, 연구자들 사이에서 eClinical 솔루션의 이점에 대한 인식 부족 등 몇 가지 장애 요인도 있습니다.
| 조사 범위 |
| 조사 대상 기간 |
2022-2029년 |
| 기준년도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
가치(10억 달러) |
| 부문 |
제품별, 출시 모델별, 용도별, 임상시험 단계별, 최종 사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카 |
2023년 데이터 수집 부문은 용도별로 eClinical 솔루션 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 이러한 성장은 주로 수작업 오류를 줄이고 데이터 입력 속도를 높이며 데이터에 대한 실시간 액세스를 통해 프로세스를 간소화하는 전자 데이터 캡처(EDC) 시스템과 같은 솔루션, 엄격한 규제 표준을 준수하고 원격 및 분산형 임상시험을 지원하는 솔루션, 수집된 데이터의 무결성 및 수집된 데이터의 정확성을 보장하기 위한 수집된 데이터의 무결성과 품질을 보장하는 것이 임상시험의 성공에 있어 점점 더 중요해짐에 따라 그 필요성이 증가하고 있습니다.
2023년 제약회사와 바이오 제약회사는 최종 사용자별로 eClinical 솔루션 시장에서 가장 큰 비중을 차지했습니다. 이러한 우위는 주로 임상시험 및 의약품 개발에 대한 기업의 막대한 투자에 기인합니다. 이들 기업은 혁신적인 의약품과 치료법을 시장에 출시하기 위해 수많은 임상시험을 수행하고 있으며, 관련 복잡한 프로세스를 관리하기 위해 크게 개선된 eClinical 시스템을 필요로 합니다. 또한, 이들 조직은 eClinical 솔루션에 투자할 수 있는 막대한 자금을 보유하고 있기 때문에 최첨단 기술과 개발을 채택할 수 있어 업계가 활기를 띠고 있습니다.
2023년 eClinical 솔루션 시장에서 가장 큰 점유율을 차지한 지역은 북미였습니다. 이 부문에서 가장 높은 점유율을 차지한 이유는 선진적인 의료 인프라, 대규모 R&D 투자, 엄격한 규제 환경 때문입니다. 대규모 임상시험을 수행하는 Pfizer, Johnson & Johnson과 같은 대형 제약회사들이 이러한 솔루션에 대한 수요를 증가시키고 있습니다. 이 지역의 높은 디지털 리터러시 수준과 메디데이터 솔루션즈(Medidata Solutions)와 같은 기업들의 혁신이 eClinical 솔루션의 광범위한 사용을 촉진하고 있으며, FDA의 21 CFR Part 11과 같은 규제 프레임워크의 가용성은 규정 준수를 보장합니다. 컴플라이언스를 보장하는 동시에 고급 데이터 관리 및 임상시험 솔루션에 대한 수요가 증가하고 있습니다.
이 보고서는 세계 eClinical 솔루션 시장을 조사했으며, 제품별/배포 모델별/용도별/임상시험 단계별/최종 사용자별/지역별 동향, 시장 진출기업 프로파일 등을 정리한 보고서입니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 생태계 분석
- 사례 연구 분석
- 밸류체인 분석
- Porter의 Five Forces 분석
- 규제 상황
- 특허 분석
- 기술 분석
- 업계 동향
- 가격 분석
- 2024-2025년 주요 컨퍼런스 및 이벤트
- 주요 이해관계자와 구입 기준
- 고객의 비즈니스에 영향을 미치는 동향과 혼란
- 최종사용자 분석
- 투자와 자금조달 시나리오
- AI/생성형 AI가 eClinical 솔루션 시장에 미치는 영향
제6장 eClinical 솔루션 시장(제품별)
- 서론
- 전자 데이터 캡처 및 임상 데이터 관리 솔루션
- 임상시험 관리 솔루션
- 임상 분석 플랫폼
- 랜덤화 및 임상시험 공급 관리 솔루션
- 전자 임상 결과 평가 솔루션
- 전자 재판 마스터 파일 솔루션
- 전자 동의 솔루션
- 규제 정보 관리 솔루션
- 임상 데이터 통합 플랫폼
- 안전 솔루션
- 기타
제7장 eClinical 솔루션 시장(전개 모델별)
- 서론
- 웹 호스트형 및 클라우드 기반 모델
- 온프레미스 모델
제8장 eClinical 솔루션 시장(용도별)
- 서론
- 데이터 수집
- 문서 관리 및 보관
- 비품 관리
- 데이터 분석
- 임상시험 업무
- 규제 정보 관리
- 기타
제9장 eClinical 솔루션 시장(임상시험 단계별)
제10장 eClinical 솔루션 시장(최종사용자별)
- 서론
- 제약 및 바이오의약품 기업
- CRO
- 컨설팅 서비스 회사
- 의료기기 제조업체
- 병원 및 헤르스케프로바이더
- 학술연구기관
- 정부기관
- 기타
제11장 eClinical 솔루션 시장(지역별)
- 서론
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
제12장 경쟁 구도
- 서론
- 주요 시장 진출기업의 전략/비책
- 매출 분석, 2019-2023년
- 시장 점유율 분석, 2023년
- 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 평가와 재무 지표
- 브랜드/제품 비교
- 경쟁 시나리오
제13장 기업 개요
- 주요 시장 진출기업
- MEDIDATA(A DASSAULT SYSTEMES COMPANY)
- VEEVA SYSTEMS
- IQVIA INC.
- ICON PLC
- ORACLE
- SIGNANT HEALTH
- CLARIO
- ECLINICAL SOLUTIONS
- CLINION
- MAXISIT
- 4G CLINICAL
- FOUNTAYN
- SAAMA
- MEDNET
- ADVARRA
- CAIDYA
- OPENCLINICA, LLC
- EVIDENTIQ
- 기타 기업
- RESEARCH MANAGER
- ANJU SOFTWARE INC.
- MEDRIO
- CASTOR
- REALTIME SOFTWARE SOLUTIONS, LLC
- YPRIME, LLC.
- VIAL
제14장 부록
LSH
The global eClinical solutions market is projected to reach USD 22.1 billion by 2029 from USD 11.6 billion in 2024, at a high CAGR of 13.7% during the forecast period. Growth Drivers include the rising operational costs and regulatory obligations for all clinical research studies, adoption of innovative software solutions for clinical research, favourable government funding received for clinical trials, rising need for better standardization and quality of clinical data, and growing R&D expenditure on drug development by pharmaceutical-biotech companies. There are some inhibitive factors, such as the high rate of implementation of eClinical solutions, scarcity of skilled professionals to implement and manage these solutions, and inadequate awareness about the benefits of eClinical solutions among researchers.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD Billion) |
| Segments | Product, Deployment Model, Application, Clinical Trial Phase, End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America and Middle East and Africa |
"In 2023, data collection segment constituted the largest segment in the eClinical solutions market, by application."
In 2023, the data collection segment accounted for the biggest proportion of the eClinical solutions market, by application. This growth is primarily driven by solutions such as electronic data capture (EDC) systems, which streamline the process by reducing manual errors, speeding up data entry, and allowing for real-time access to data; the growing need to comply with stringent regulatory standards and support remote and decentralised trials; and its growing importance in clinical trial success, as it ensures the integrity and quality of the data being gathered.
"In 2023, the pharmaceutical & biopharmaceutical companies held the largest market share among end users."
In 2023, pharmaceutical and biopharmaceutical firms accounted for the highest proportion of the eClinical solutions market by end user. This dominance stems primarily from the enormous number of corporations' investments in clinical trials and drug development. These companies run numerous clinical studies to get their innovative medications and cures to market, necessitating significantly improved eClinical systems to manage the complicated processes involved. Furthermore, these organizations have significant financial resources to invest in eClinical solutions, allowing them to adopt cutting-edge technology and developments, hence, fueling the industry.
"In 2023, North America was the largest regional market for eClinical solutions market."
In 2023, North America had the highest share of the eClinical Solutions market. This segment's highest share is attributed to its advanced healthcare infrastructure, major R&D investments, and strict regulatory environment. Big Pharma companies like Pfizer and Johnson & Johnson that conduct clinical trials on a large scale are the ones responsible for the high demand of these solutions. The region's high digital literacy and technological innovation given by companies such as Medidata Solutions propel the widespread use of eClinical solutions. The availability of regulatory frameworks, such as the FDA's 21 CFR Part 11, ensures compliance while driving up demand for sophisticated data management and clinical trial solutions.
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
- By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
Key Players in the eClinical Solutions Market
The key players functioning in the EClinical solutions market include Medidata (A Dassault Systemes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
Research Coverage:
The report analyses the eClinical solutions market. It aims to estimate the market size and future growth potential of various market segments based on product, deployment model, application, clinical trial phase, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of key drivers: (increasing operational costs and regulatory requirements associated with clinical research studies), restraints (high implementation costs associated with eClinical solutions), opportunities (growing number of clinical trials in developing nations), and challenges (concerns pertaining to patient privacy) influencing the growth of the eClinical solutions market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the eClinical solutions market.
- Market Development: Comprehensive information on the lucrative emerging markets, products, deployment models, applications, clinical trial phase, end-users, and regions.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the eClinical solutions market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the eClinical solutions market like Medidata (A Dassault Systemes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED
- 1.3.2 YEARS CONSIDERED
- 1.3.3 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
- 1.5.1 IMPACT OF AI/GEN AI
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 Insights from primary experts
- 2.2 MARKET SIZE ESTIMATION
- 2.3 DATA TRIANGULATION
- 2.4 MARKET SHARE ESTIMATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.6.1 METHODOLOGY-RELATED LIMITATIONS
- 2.6.2 SCOPE-RELATED LIMITATIONS
- 2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW
- 4.2 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE AND COUNTRY, 2024
- 4.3 ECLINICAL SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 ECLINICAL SOLUTIONS MARKET REGIONAL MIX
- 4.5 ECLINICAL SOLUTIONS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing focus on cost-effective processes
- 5.2.1.2 Favorable government support and funding
- 5.2.1.3 Need for data standardization
- 5.2.1.4 Increasing R&D expenditure on drug development
- 5.2.2 RESTRAINTS
- 5.2.2.1 High implementation costs
- 5.2.2.2 Lack of skilled professionals
- 5.2.2.3 Limited awareness among researchers
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing number of clinical trials
- 5.2.3.2 Outsourcing of clinical trials
- 5.2.3.3 Gradual shift toward real-time data analysis
- 5.2.4 CHALLENGES
- 5.2.4.1 Limited adoption in developing and underdeveloped countries
- 5.2.4.2 Software reliability issues
- 5.2.4.3 Patient privacy concerns
- 5.3 ECOSYSTEM ANALYSIS
- 5.3.1 HEALTHCARE PROVIDERS
- 5.3.2 CLOUD PROVIDERS
- 5.3.3 GOVERNMENT AGENCIES AND REGULATORY BODIES
- 5.3.4 ECLINICAL SOLUTION COMPANIES
- 5.4 CASE STUDY ANALYSIS
- 5.4.1 ENHANCED PATIENT RECORDS USING MEDIDATA ECOA APP
- 5.4.2 IMPROVED ALZHEIMER'S TREATMENT WITH LEQEMB THERAPY
- 5.4.3 EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 PORTER'S FIVE FORCES ANALYSIS
- 5.6.1 BARGAINING POWER OF SUPPLIERS
- 5.6.2 BARGAINING POWER OF BUYERS
- 5.6.3 THREAT OF SUBSTITUTES
- 5.6.4 THREAT OF NEW ENTRANTS
- 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.7 REGULATORY LANDSCAPE
- 5.7.1 REGULATORY ANALYSIS
- 5.7.1.1 North America
- 5.7.1.2 Europe
- 5.7.1.3 Asia Pacific
- 5.7.1.4 Latin America
- 5.7.1.5 Middle East & Africa
- 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.8 PATENT ANALYSIS
- 5.8.1 PATENT PUBLICATION TRENDS FOR ECLINICAL SOLUTIONS
- 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
- 5.9.1.1 AI-enabled and integrated platforms
- 5.9.1.2 Clinical data integration
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
- 5.9.2.1 Cloud computing
- 5.9.2.2 Analytical tools
- 5.9.3 ADJACENT TECHNOLOGIES
- 5.9.3.1 Electronic health records
- 5.9.3.2 Real-world data
- 5.9.3.3 Bioinformatics
- 5.10 INDUSTRY TRENDS
- 5.10.1 DECENTRALIZED CLINICAL TRIALS
- 5.10.2 TELEMEDICINE
- 5.10.3 BIG DATA
- 5.11 PRICING ANALYSIS
- 5.11.1 INDICATIVE PRICING ANALYSIS, BY DEPLOYMENT MODEL
- 5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
- 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
- 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.15 END-USER ANALYSIS
- 5.15.1 UNMET NEEDS
- 5.15.2 END-USER EXPECTATIONS
- 5.16 INVESTMENT AND FUNDING SCENARIO
- 5.17 IMPACT OF AI/GEN AI ON ECLINICAL SOLUTIONS MARKET
- 5.17.1 KEY USE CASES
- 5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
- 5.17.2.1 Case study
- 5.17.2.2 Clinical trial management system market
- 5.17.2.3 Clinical trial market
- 5.17.2.4 Electronic clinical outcome assessment solution market
- 5.17.3 USER READINESS AND IMPACT ASSESSMENT
- 5.17.3.1 User readiness
- 5.17.3.1.1 Pharmaceutical and biopharmaceutical companies
- 5.17.3.1.2 Contract research organizations
- 5.17.3.2 Impact assessment
- 5.17.3.2.1 User A: Pharmaceutical & biopharmaceutical companies
- 5.17.3.2.1.1 Implementation
- 5.17.3.2.1.2 Impact
- 5.17.3.2.2 User B: Academic research institutes
- 5.17.3.2.2.1 Implementation
- 5.17.3.2.2.2 Impact
6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SOLUTIONS
- 6.2.1 RISING NEED TO REDUCE TIME AND COSTS IN CLINICAL TRIALS TO ENCOURAGE GROWTH
- 6.3 CLINICAL TRIAL MANAGEMENT SOLUTIONS
- 6.3.1 RISING DEMAND FOR SITE & DATA COLLECTION SOLUTIONS TO FACILITATE GROWTH
- 6.4 CLINICAL ANALYTICS PLATFORMS
- 6.4.1 GROWING ADOPTION OF ELECTRONIC MEDICAL RECORDS TO BOOST MARKET
- 6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SOLUTIONS
- 6.5.1 GROWING TREND OF GLOBALIZATION TO FUEL MARKET
- 6.6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
- 6.6.1 INCREASING ADOPTION OF EDIARIES TO AID GROWTH
- 6.7 ELECTRONIC TRIAL MASTER FILE SOLUTIONS
- 6.7.1 IMPROVED INFORMATION SEARCH AND RETRIEVAL TO FUEL MARKET
- 6.8 ELECTRONIC CONSENT SOLUTIONS
- 6.8.1 GROWING INCLINATION TOWARD DIGITIZATION TO PROMOTE GROWTH
- 6.9 REGULATORY INFORMATION MANAGEMENT SOLUTIONS
- 6.9.1 ENHANCED REGULATORY SUBMISSION PROCESS TO AUGMENT GROWTH
- 6.10 CLINICAL DATA INTEGRATION PLATFORMS
- 6.10.1 GROWING VOLUME OF CLINICAL DATA AND IMPROVED CLOUD TECHNOLOGY TO PROPEL MARKET
- 6.11 SAFETY SOLUTIONS
- 6.11.1 GROWING ADOPTION OF ECLINICAL SOFTWARE TO SUPPORT MARKET GROWTH
- 6.12 OTHER SOLUTIONS
7 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL
- 7.1 INTRODUCTION
- 7.2 WEB-HOSTED & CLOUD-BASED MODELS
- 7.2.1 GROWING DEMAND FOR CLOUD-BASED SOLUTIONS TO AUGMENT GROWTH
- 7.3 ON-PREMISE MODELS
- 7.3.1 MINIMIZED DATA BREACHES AND EXTERNAL ATTACK RISKS TO SUPPORT MARKET
8 ECLINICAL SOLUTIONS MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 DATA COLLECTION
- 8.2.1 IMPROVED TRIAL EFFICIENCY TO DRIVE MARKET
- 8.3 DOCUMENT MANAGEMENT & STORAGE
- 8.3.1 RISING INCLINATION TOWARD STREAMLINED DOCUMENT WORKFLOWS TO FUEL MARKET
- 8.4 SUPPLY MANAGEMENT
- 8.4.1 NEED TO ADDRESS COMPLEXITIES IN MANAGING CLINICAL TRIAL SUPPLIES TO BOOST MARKET
- 8.5 DATA ANALYTICS
- 8.5.1 INCREASING NEED FOR OPTIMIZED TRIAL DESIGNS TO AID GROWTH
- 8.6 CLINICAL TRIAL OPERATIONS
- 8.6.1 GROWING FOCUS ON ENHANCED DRUG DEVELOPMENT TO PROPEL MARKET
- 8.7 REGULATORY INFORMATION MANAGEMENT
- 8.7.1 EVOLVING GLOBAL REGULATORY STANDARDS TO STIMULATE GROWTH
- 8.8 OTHER APPLICATIONS
9 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE
- 9.1 INTRODUCTION
- 9.2 PHASE I
- 9.2.1 INCREASING DEMAND FOR ACCURATE CLINICAL DATA MANAGEMENT TO ACCELERATE GROWTH
- 9.3 PHASE II
- 9.3.1 PUSH TOWARD FASTER DRUG DEVELOPMENT TO FACILITATE GROWTH
- 9.4 PHASE III
- 9.4.1 INVOLVEMENT OF LARGE PATIENT POPULATION TO ENCOURAGE SEGMENT GROWTH
- 9.5 PHASE IV
- 9.5.1 GROWING EMPHASIS ON SAFE DRUGS TO DRIVE MARKET
10 ECLINICAL SOLUTIONS MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 10.2.1 INCREASING R&D EXPENDITURE TO DRIVE MARKET
- 10.3 CONTRACT RESEARCH ORGANIZATIONS
- 10.3.1 GROWING OUTSOURCING OF CLINICAL TRIALS TO FUEL MARKET
- 10.4 CONSULTING SERVICE COMPANIES
- 10.4.1 INCREASING COMPLEXITIES AND COSTS OF CLINICAL DATA MANAGEMENT TO PROPEL MARKET
- 10.5 MEDICAL DEVICE MANUFACTURERS
- 10.5.1 RISING DEVELOPMENT OF NEW MEDICAL DEVICES TO BOOST MARKET
- 10.6 HOSPITALS & HEALTHCARE PROVIDERS
- 10.6.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND ECLINICAL SOLUTION PROVIDERS TO STIMULATE MARKET
- 10.7 ACADEMIC & RESEARCH INSTITUTES
- 10.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO EXPEDITE GROWTH
- 10.8 GOVERNMENT ORGANIZATIONS
- 10.8.1 INCREASED ADOPTION BY HEALTH DEPARTMENTS AND REGULATORY BODIES TO SPEED UP GROWTH
- 10.9 OTHER END USERS
11 ECLINICAL SOLUTIONS MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.2.2 US
- 11.2.2.1 Rising government funding for pharmaceutical R&D to drive market
- 11.2.3 CANADA
- 11.2.3.1 Advanced facilities and shorter approval times for drug candidates to fuel market
- 11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.3.2 GERMANY
- 11.3.2.1 High number of sponsored clinical trials to augment growth
- 11.3.3 UK
- 11.3.3.1 Increased investments by pharmaceutical companies to boost market
- 11.3.4 FRANCE
- 11.3.4.1 Booming generics market to aid growth
- 11.3.5 ITALY
- 11.3.5.1 Favorable drug approval scenario to support market growth
- 11.3.6 SPAIN
- 11.3.6.1 Robust network of research centers, universities, and hospitals to encourage growth
- 11.3.7 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.4.2 CHINA
- 11.4.2.1 Low manufacturing costs and huge demand for medicines to expedite growth
- 11.4.3 INDIA
- 11.4.3.1 Growing foreign direct investments to facilitate market growth
- 11.4.4 JAPAN
- 11.4.4.1 Drug discovery and development initiatives to promote growth
- 11.4.5 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 11.5.2 BRAZIL
- 11.5.2.1 Higher adoption of advanced digital technologies to stimulate growth
- 11.5.3 MEXICO
- 11.5.3.1 Government initiatives to enhance digital infrastructure of healthcare to propel market
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST & AFRICA
- 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 11.6.2 GCC COUNTRIES
- 11.6.2.1 Growing modernization initiatives in healthcare sector to support market growth
- 11.6.3 REST OF MIDDLE EAST & AFRICA
12 COMPETITIVE LANDSCAPE
- 12.1 INTRODUCTION
- 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 12.3 REVENUE ANALYSIS, 2019-2023
- 12.4 MARKET SHARE ANALYSIS, 2023
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 12.5.5.1 Company footprint
- 12.5.5.2 Product footprint
- 12.5.5.3 Application footprint
- 12.5.5.4 End-user footprint
- 12.5.5.5 Region footprint
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.6.1 PROGRESSIVE COMPANIES
- 12.6.2 RESPONSIVE COMPANIES
- 12.6.3 DYNAMIC COMPANIES
- 12.6.4 STARTING BLOCKS
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.7 COMPANY EVALUATION AND FINANCIAL METRICS
- 12.8 BRAND/PRODUCT COMPARISON
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
- 13.1 KEY PLAYERS
- 13.1.1 MEDIDATA (A DASSAULT SYSTEMES COMPANY)
- 13.1.1.1 Business overview
- 13.1.1.2 Products offered
- 13.1.1.3 Recent developments
- 13.1.1.3.1 Product launches and enhancements
- 13.1.1.3.2 Deals
- 13.1.1.4 MnM view
- 13.1.1.4.1 Right to win
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 VEEVA SYSTEMS
- 13.1.2.1 Business overview
- 13.1.2.2 Products offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Product launches and enhancements
- 13.1.2.3.2 Deals
- 13.1.2.4 MnM view
- 13.1.2.4.1 Right to win
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 IQVIA INC.
- 13.1.3.1 Business overview
- 13.1.3.2 Products offered
- 13.1.3.3 Recent developments
- 13.1.3.4 MnM view
- 13.1.3.4.1 Right to win
- 13.1.3.4.2 Strategic choices
- 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 ICON PLC
- 13.1.4.1 Business overview
- 13.1.4.2 Products offered
- 13.1.4.3 Recent developments
- 13.1.4.3.1 Product launches and enhancements
- 13.1.4.3.2 Deals
- 13.1.5 ORACLE
- 13.1.5.1 Business overview
- 13.1.5.2 Products offered
- 13.1.5.3 Recent developments
- 13.1.6 SIGNANT HEALTH
- 13.1.6.1 Business overview
- 13.1.6.2 Products offered
- 13.1.6.3 Recent developments
- 13.1.6.3.1 Product launches and enhancements
- 13.1.6.3.2 Deals
- 13.1.7 CLARIO
- 13.1.7.1 Business overview
- 13.1.7.2 Products offered
- 13.1.7.3 Recent developments
- 13.1.7.3.1 Product launches and enhancements
- 13.1.7.3.2 Deals
- 13.1.7.3.3 Other developments
- 13.1.8 ECLINICAL SOLUTIONS
- 13.1.8.1 Business overview
- 13.1.8.2 Products offered
- 13.1.8.3 Recent developments
- 13.1.8.3.1 Product launches and enhancements
- 13.1.8.3.2 Deals
- 13.1.9 CLINION
- 13.1.9.1 Business overview
- 13.1.9.2 Products offered
- 13.1.9.3 Recent developments
- 13.1.9.3.1 Product launches and enhancements
- 13.1.9.3.2 Deals
- 13.1.10 MAXISIT
- 13.1.10.1 Business overview
- 13.1.10.2 Products offered
- 13.1.11 4G CLINICAL
- 13.1.11.1 Business overview
- 13.1.11.2 Products offered
- 13.1.11.3 Recent developments
- 13.1.12 FOUNTAYN
- 13.1.12.1 Business overview
- 13.1.12.2 Products offered
- 13.1.13 SAAMA
- 13.1.13.1 Business overview
- 13.1.13.2 Products offered
- 13.1.13.3 Recent developments
- 13.1.14 MEDNET
- 13.1.14.1 Business overview
- 13.1.14.2 Products offered
- 13.1.14.3 Recent developments
- 13.1.14.3.1 Product launches and enhancements
- 13.1.14.3.2 Deals
- 13.1.15 ADVARRA
- 13.1.15.1 Business overview
- 13.1.15.2 Products offered
- 13.1.15.3 Recent developments
- 13.1.15.3.1 Product launches and enhancements
- 13.1.15.3.2 Deals
- 13.1.16 CAIDYA
- 13.1.16.1 Business overview
- 13.1.16.2 Products offered
- 13.1.16.3 Recent developments
- 13.1.16.3.1 Deals
- 13.1.16.3.2 Expansions
- 13.1.17 OPENCLINICA, LLC
- 13.1.17.1 Business overview
- 13.1.17.2 Products offered
- 13.1.17.3 Recent developments
- 13.1.18 EVIDENTIQ
- 13.1.18.1 Business overview
- 13.1.18.2 Products offered
- 13.1.18.3 Recent developments
- 13.1.18.3.1 Product launches and enhancements
- 13.1.18.3.2 Deals
- 13.2 OTHER PLAYERS
- 13.2.1 RESEARCH MANAGER
- 13.2.2 ANJU SOFTWARE INC.
- 13.2.3 MEDRIO
- 13.2.4 CASTOR
- 13.2.5 REALTIME SOFTWARE SOLUTIONS, LLC
- 13.2.6 YPRIME, LLC.
- 13.2.7 VIAL
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
